HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online August 14 in ...

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

China NMPA grants breakthrough therapy designation to Antengene’s ATG-022 to treat gastric/gastroesophageal junction adenocarcinoma: Shanghai Wednesday, August 20, 2025, 16:00 H ...

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...

PD-1 Inhibitor Drug PD-1 Inhibitor Drugs Market poised for robust growth, driven by rising cancer therapies and expanding immuno-oncology a ...

Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American ...

Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43 ...

Harrogate resident, Jackie Swainston, is taking on an epic Land’s End to John o’Groats cycling challenge on 7 September 2025 ...